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The type I interferon (IFN) system plays an important role in controlling herpesvirus infec-
tions, but it is unclear which IFN-mediated effectors interfere with herpesvirus replication.
Here we report that human myxovirus resistance protein B (MxB, also designated Mx2) is a
potent human herpesvirus restriction factor in the context of IFN. We demonstrate that
ectopic MxB expression restricts a range of herpesviruses from the Alphaherpesvirinae and
Gammaherpesvirinae, including herpes simplex virus 1 and 2 (HSV-1 and HSV-2), and Kaposi’s
sarcoma-associated herpesvirus (KSHV). MxB restriction of HSV-1 and HSV-2 requires
GTPase function, in contrast to restriction of lentiviruses. MxB inhibits the delivery of
incoming HSV-1 DNA to the nucleus and the appearance of empty capsids, but not the capsid
delivery to the cytoplasm or tegument dissociation from the capsid. Our study identiﬁes MxB
as a potent pan-herpesvirus restriction factor which blocks the uncoating of viral DNA from
the incoming viral capsid.
DOI: 10.1038/s41467-018-04379-2 OPEN
1 Institute of Medical Virology, University of Zurich, Winterthurerstrasse 190, 8057 Zürich, Switzerland. 2 Life Science Zurich Graduate School,
Winterthurerstrasse 190, 8057 Zürich, Switzerland. 3 Institute of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, 8057 Zürich,
Switzerland. 4 Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zürich, Switzerland. 5 Institute of Virology,
University of Zurich, Winterthurerstrasse 266a, 8057 Zürich, Switzerland. 6 Department of Neurosurgery and Neuropathology, University Hospital Zurich,
Frauenklinikstrasse 10, 8091 Zürich, Switzerland. These authors contributed equally: Cornel Fraefel, Urs F. Greber. Correspondence and requests for materials
should be addressed to J.P. (email: pavlovic.jovan@virology.uzh.ch)
NATURE COMMUNICATIONS |  (2018) 9:1980 | DOI: 10.1038/s41467-018-04379-2 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
V iruses are ubiquitous and affect all forms of life. Inhumans, livestock and plants, they cause disease byrecurrent or chronic infections, and have had a major
impact on human evolution. For example, viruses inﬂuenced the
emergence and maintenance of elaborate host defence systems,
such as innate and adaptive immunity1–4. In the course of an
infection, viruses elicit danger signals, and trigger cell-based
innate immunity owing to viral components, including virions,
viral proteins and nucleic acids, and cell damage5,6. A major
branch of mammalian innate immunity against viruses is the
interferon (IFN) system7. This system comprises type I, II and III
IFN, and involves hundreds of IFN-stimulated genes (ISGs). ISG
expression can lead to the so-called restriction factors which
directly inhibit a process essential to the production of virus
progeny, or ISG expression can act indirectly by building up an
elaborate antiviral network8.
Human myxovirus resistance protein B (MxB) has recently
been identiﬁed as an IFN-induced restriction factor of human
immunodeﬁciency virus type 1 (HIV-1) and other primate
lentiviruses9–11. MxB is a member of the dynamin-like large
GTPases and is closely related to MxA, an ISG product with
broad antiviral activity against a multitude of RNA viruses and
some DNA viruses but not against herpes simplex virus 1 (HSV-
1) or HIV-19,12,13. At the subcellular level, MxB can be found in
the cytoplasm, on the cytoplasmic face of nuclear membranes
and in the nucleus10,12,14. Under certain conditions, MxB has
been shown to bind to HIV-1 capsid-like recombinant assem-
blies via its amino-terminal domain15–17. This has been taken as
evidence that MxB prevents uncoating of proviral DNA from
incoming HIV-1 capsids. The antivirally active form of MxB is
likely an antiparallel dimer and the formation of higher-order
oligomeric structures does not appear to be required to exert full
antiviral function15,18. However, binding of MxB to HIV-1
capsids is clearly not sufﬁcient for the observed antiviral activity,
since MxB retains binding capacity to capsid mutants that are
resistant to the antiviral effect of MxB15. Intriguingly, the GTP-
hydrolysing function of MxB appears to be dispensable for the
antiviral activity against HIV-19,10,19, which stands in contrast
to the antiviral activity of MxA that requires GTPase
function13,20. Antiviral activity of MxB is likely not restricted to
HIV-1, as indicated by a recent analysis of MX2 (the gene
encoding MxB) evolution21. In their study, Mitchell et al.21
found that amino acid residues, which are important for anti-
lentivirus activity, have not evolved under diversifying selection
in primates, indicating that MxB functions beyond lentivirus
restriction. We therefore evaluated whether other human viru-
ses, which replicate in the nucleus, are restricted by MxB and
focused on HSV-1 and human adenovirus C serotype 5 (HAdV-
C5).
HAdV-C5 is a widespread human pathogen of the respiratory
tracts and is life-threatening in immunosuppressed individuals22.
Its replication is suppressed by IFN and can lead to persistent
infection with low levels of virus production23. HAdV-C5 enters
epithelial cells by clathrin-dependent and clathrin-independent,
dynamin-2-dependent endocytosis24. It escapes from non-
acidiﬁed early endosomes, is transported by dynein-dependent
and microtubule-dependent transport to the nucleus, binds and
uncoats at the nuclear pore complex (NPC) and imports a
double-stranded linear DNA genome in complex with viral
proteins into the nucleus25–30. Adenovirus intercepts IFN
restriction by its immediate-early protein E1A, which inhibits the
E3 ubiquitin ligase hBre1, and thereby results in transcriptional
suppression of ISGs31,32.
Human herpesviruses are prevalent in humans, and cause
disease ranging from subclinical manifestations to encephalitis
and cancer, particularly in immunocompromised individuals.
Members of each subfamily Alphaherpesvirinae, Betaherpesvir-
inae and Gammaherpesvirinae establish lifelong persistence by
latent infections. The virions contain a double-stranded DNA
genome wrapped in an icosahedral capsid surrounded by a pro-
teinaceous layer referred to as tegument, and a lipid envelope that
harbours the glycoproteins required for entry into host cells.
Entry can either occur through fusion of the viral envelope with
the plasma membrane or by endocytosis33,34. Upon entry, the
tegument gradually dissociates and the capsid is transported
along microtubules to the nuclear envelope. Injection of the viral
genomic DNA into the nucleus occurs at the NPC in a process
that involves tegument and capsid proteins as well as cellular
nuclear import factors and nucleoporins (reviewed in Refs. 35–38).
Nuclear entry is followed by transcription of immediate-early
genes including RL2, encoding the infected cell protein 0 (ICP0),
which in turn drives HSV-1 early and late gene expression and is
required for efﬁcient replication.
Incoming herpesviruses trigger a pronounced innate immune
response including the production of type I IFN39,40. Although
the recognition of herpesviruses by pattern recognition receptors
mediating IFN synthesis has been studied extensively (reviewed in
Refs. 41–43), little is known about the IFN-induced effector
mechanisms that result in the inhibition of virus replication.
Several ISGs with antiviral function such as the dsRNA-
dependent protein kinase R (PKR), viperin, tetherin, zinc-ﬁnger
antiviral protein and 2′–5′ oligoadenylate synthetase (OAS) have
been implicated in restricting herpesviruses, but their contribu-
tion remains to be elucidated (reviewed in Refs. 44,45).
Here we report that MxB efﬁciently blocks herpesvirus infec-
tion at an early post-entry step, which precludes the nuclear
translocation of the incoming viral DNA.
Results
Interferon-induced MxB inhibits HSV-1 replication. To assess
the impact of MxB expression on HSV-1 infection, we transfected
T98G glioblastoma cells known to express high levels of MxB in
response to type I IFN46 (see also Supplementary Fig. 1a) with
non-targeting control small interfering RNA (siRNA) (siNT) and
MX2-targeting siRNAs (siMxB 3'-untranslated region (UTR),
siMxB #1). MxB was expressed in IFN-α2-treated cells transfected
with control siRNA, where it accumulated at the nuclear envelope
as well as in the cytoplasm, as previously described10,47. Trans-
fection with MX2-speciﬁc siRNAs prevented the accumulation of
MxB to detectable levels (Fig. 1a–c). Infection of siNT-transfected
T98G cells with two distinct HSV-1 strains (MacIntyre and F)
yielded viral titres of approximately 5 × 107 TCID50/ml. In order
to exclude non-speciﬁc effects of siRNA transfection, relative
titres are shown (Fig. 1b, c). Pretreatment of T98G cells with 500
IU/ml IFN-α2 reduced viral titres of both strains approximately
1000-fold. Remarkably, in T98G cells transfected with siRNAs
speciﬁc forMX2, the observed IFN-mediated inhibition of HSV-1
infection was partially released, resulting in approximately 10-
fold increased viral titres (Fig. 1b, c). Increased titres in cells
transfected with MX2-speciﬁc siRNAs were reﬂected in markedly
enhanced levels of HSV-1 virion protein 16 (VP16) when com-
pared to cells transfected with control siRNA (Fig. 1b, c).
We next monitored the inﬂuence of MxB expression on HSV-1
growth in an infection kinetics experiment by employing a live-
cell ﬂuorescence imaging system and a recombinant HSV-1 strain
encoding green ﬂuorescent protein (GFP, strain C1248). We
infected T98G cells with C12 virus following transfection with
non-targeting or MX2-speciﬁc siRNAs and stimulation with IFN-
α2. In the absence of IFN-α2 stimulation, the C12 strain grew
rapidly, reaching maximal GFP signal (40–56 arbitrary units (a.
u.)) between 60 and 72 h post infection (p.i.), irrespective of the
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siRNA used (Fig. 1d and Supplementary Fig. 1b). By contrast, in
IFN-α2-stimulated cells transfected with non-targeting siRNA,
HSV-1 grew slowly, reaching approximately 6 a.u. at 72 h p.i. In
cells pretreated with MX2-speciﬁc siRNAs, however, the block
was gradually released and GFP signals reached between 27% and
45% of the IFN-α2-untreated controls (Fig. 1d). Hence, MxB
contributes signiﬁcantly to the IFN-mediated inhibition of
HSV-1 infection. As a control, we performed an analogous
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experiment using two siRNAs targeting the coding region of PKR,
an ISG with known anti-HSV-1 activity44. The observed PKR
siRNA-dependent release of HSV-1 restriction resulted in
22–26% of viral growth compared to the untreated controls
(Supplementary Figs. 1c, d and 7d). We therefore concluded that
in this setting, the potential of MxB to restrict HSV-1 is
comparable to PKR.
Overexpression of MxB inhibits herpesvirus growth. We next
tested whether ectopic expression of MxB in the absence of IFN-
α2 stimulation would restrict HSV-1 and other members of the
Herpesviridae family. For this purpose, we generated several
stably transduced A549 and Vero cell clones constitutively
expressing glutathione S-transferase M1 (GST, control) or MxB
by means of lentiviral vectors. In MxB-expressing A549 cells,
ectopic MxB was found at the nuclear membrane and in a
punctate pattern in the cytoplasm (Fig. 2a). A similar phenotype
was observed in Vero cells stably overexpressing MxB (Supple-
mentary Fig. 2c). Transfection with siRNAs against the coding
region of MX2 (siMxB #1, siMxB #2) reduced the level of MxB
expression to about 30% or less of the control (siNT), whereas an
siRNA against the 3′-UTR of the endogenous MX2 mRNA
(siMxB UTR) not present in the overexpressed gene had no
inhibitory effect (Fig. 2b and Supplementary Fig. 2d). Control
infection of A549-GST and A549-MxB cell clones with the HIV-
1-based luciferase reporter virus NL-Luc49 and inﬂuenza A virus
(IAV) conﬁrmed that MxB restricts replication of HIV-1 but not
IAV9–12 (Supplementary Fig. 5b and Fig. 2c). Vesicular stomatitis
virus (VSV) was previously reported to be inhibited by MxB50. In
our cell culture system, we observed a ﬁvefold reduction of VSV
infection in cells expressing MxB as compared to GST (Fig. 2d).
Further, we tested whether MxB would inhibit growth of human
HAdV-C5. We observed a 2.4-fold reduction of HAdV-C5 titres
in multi-round infections of A549-MxB cells (Fig. 2e), and an
inhibition of GFP expression in single-round infections using
GFP or late viral protein expression as a readout (Supplementary
Fig. 5c). However, transfection of siRNA against MX2 did not
restore HAdV-C5 reporter gene expression, suggesting that the
effects of MxB on HAdV-C5 infection were indirect or unspeciﬁc
(Supplementary Fig. 5d). In contrast, we found that MxB
expression had a pronounced negative effect on several repre-
sentatives of the Alphaherpesvirinae subfamily. In our experi-
ments, we used stocks of three different HSV-1 strains
(MacIntyre, F or C12) grown under identical conditions. When
we challenged A549 cells expressing MxB with these three strains,
viral titres were reduced about 75-fold as compared to A549-GST
cells (Fig. 2f–h). Similarly, the commonly used HSV-2 strain G
showed a reduction of approximately 50-fold (Fig. 2i). Trans-
fection of an siRNA against the 3′-UTR of endogenous MX2
mRNA had no effect on HSV growth. On the contrary, trans-
fection with siRNAs against the coding region of MX2 largely
restored titres of all tested HSV-1 strains and HSV-2 (Fig. 2f–i).
Cell lysates prepared at the time of virus supernatant collection
revealed that HSV late protein VP16 was expressed at con-
siderably lower levels in A549-MxB cells compared to control
cells, yet VP16 expression was fully restored upon MX2 silencing
(Supplementary Fig. 7b). Importantly, siRNA transfection did not
impact herpesvirus titres or VP16 expression in A549-GST cells,
and the effect of the individual siRNAs on cell viability in the
different cell lines was negligible, thereby excluding unspeciﬁc
effects of the different siRNAs used in this system (Supplemen-
tary Fig. 7a). In order to rule out possible effects of individual cell
clones on HSV titres, two additional, independently generated
A549-MxB cell clones (MxB_2 and MxB_3) were tested for
restriction of HSV-1 strain C12 and HSV-2. Both additional
A549-MxB clones inhibited HSV-1 and HSV-2 to the same extent
as the original A549-MxB clone, and this effect was again reverted
with MX2-speciﬁc siRNAs (Supplementary Fig. 2a, b). The fact
that the rescue of the HSV titres was not always complete
(Fig. 2f–i, Supplementary Fig. 2b) may be due to incomplete
silencing of MX2 expression in A549-MxB cells at the time of
infection (Fig. 2b and Supplementary Fig. 7e). In Vero cells, the
MxB-mediated inhibition of HSV-1 replication was readily
measurable but less pronounced as compared to A549 cells
(Supplementary Fig. 2e). We then tested whether Kaposi’s
sarcoma-associated herpesvirus (KSHV), a representative of the
Gammaherpesvirinae subfamily, was restricted by MxB in A549
cells. Here, we made use of a recombinant KSHV that expresses
GFP upon virus entry into the host cell nucleus and red ﬂuor-
escent protein (RFP) upon lytic reactivation51. While KSHV was
detected in 79–88% of A549 cells expressing GST, only 27–31% of
A549 cells expressing MxB showed a detectable level of KSHV
infection (Fig. 3a). Pretreatment of A549-MxB cells with MX2-
speciﬁc siRNAs siMxB #1 and siMxB #2 resulted in a strong
rescue of KSHV infectivity (58–62% in A549-MxB cells compared
to 70–87% in A549-GST cells, Fig. 3a). Moreover, we employed
immunoﬂuorescence assays to assess the accumulation of latency-
associated nuclear antigen (LANA), one of the three main KSHV
proteins expressed during persistent latent infection. Endogenous
LANA staining is widely used to detect KSHV infection, as KSHV
establishes latency as a default program in various systems
in vitro and in vivo, including epithelial cells51–54. In A549-GST
Fig. 1 Interferon-induced MxB inhibits HSV-1 replication. a T98G human glioblastoma cells were transfected with non-targeting siRNA (siNT) or siRNA
targeting endogenous MX2 (siMxB UTR). At 30 h post transfection, cells were mock-stimulated or stimulated with human IFN-α2 (1000 IU/ml) for 18 h.
MxB protein expression and intracellular localisation was assessed by immunostaining. Nuclei were stained with Hoechst 33342. Scale bar, 20 µm. b, c
T98G cells were transfected with non-targeting siRNA (siNT) or two different siRNAs targeting endogenous MX2 (siMxB UTR, siMxB #1). At 30 h post
transfection, cells were mock-stimulated or stimulated with human IFN-α2 (500 IU/ml). At 48 h post transfection, cells were infected with HSV-1 strain
MacIntyre (b) or F (c) at a multiplicity of infection (MOI) of 0.1 for 32 h. Cell culture supernatants were subjected to TCID50 assay and cells were lysed and
pooled for immunoblot analysis of MxB protein expression, MX2 silencing efﬁciency and HSV-1 late protein VP16 expression. MxA served as a control for
siRNA speciﬁcity and GAPDH served as a loading control. Titres of mock-stimulated samples are each set to 100%. Bars indicate relative mean ± s.d., n= 6
biological replicates. ANOVAs modelling log-transformed relative titre with IFN and siRNA as explanatory variables: HSV-1 MacIntyre: IFN, F(1,30)=
1215.74, p < 0.0001; siRNA, F(2,30)= 13.67, p < 0.0001; antagonising interaction, F(2,30)= 14.81, p < 0.0001. HSV-1 F: IFN, F(1,30)= 587.29, p < 0.0001;
siRNA, F(2,30)= 39.55, p < 0.0001; antagonising interaction, F(2,30)= 33.63, p < 0.0001. d T98G cells were siRNA-transfected and stimulated with
human IFN-α2 as in b, but then mock-infected or infected with HSV-1 recombinant strain C12 expressing GFP (MOI= 0.1). Virus growth was determined
by real-time quantiﬁcation of GFP ﬂuorescence. Upper panel: Data points indicate the integrated green object intensity normalised to cell conﬂuence
(mean ± s.d., n= 3 biological replicates). Lower panel: Relative area under the curve from 0 to 72 h post infection. GFP signals of mock-stimulated samples
are each set to 1. Bars indicate relative mean ± s.d., n= 3 biological replicates. ANOVA modelling relative area under the curve with IFN and siRNA as
explanatory variables: IFN, F(1,12)= 23,829.4, p < 0.0001; siRNA, F(2,12)= 211.3, p < 0.0001; antagonising interaction, F(2,12)= 211.3, p < 0.0001. All data
are representative of two independent experiments. a.u., arbitrary units. Multiple comparisons: ****p < 0.0001
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cells, LANA accumulation was detected in the majority of cells
after overnight infection with KSHV (Supplementary Fig. 3a).
A549-MxB cells exhibited only 10–17% of the average signal
intensity measured in the respective control condition (Fig. 3b
and Supplementary Fig. 3a). Similarly to our results in the ﬂow
cytometry-based assay (Fig. 3a), endogenous LANA expression
was rescued upon MX2 silencing in A549-MxB cells (50–92% of
the respective control), emphasising the speciﬁcity of MxB in
restricting KSHV (Fig. 3b and Supplementary Fig. 3a). GFP and
LANA signals measured in parallel revealed a strong correlation
(Spearman’s ρ= 0.787, p < 0.0001, Supplementary Fig. 3a), which
is consistent with the notion that GFP under transcriptional
control of the eukaryotic translation elongation factor 1α
(EEF1A1) promoter can be used as a marker of KSHV infection51.
KSHV lytic gene expression, as measured by RFP expression
under the control of the KSHV lytic polyadenylated nuclear RNA
(PAN) promoter, was hardly detectable in A549 cells at 48 h p.i.,
suggesting a predominantly latent infection of these epithelial
cells. Since KSHV also exhibits a natural tropism for endothelial
cells54, we tested MxB-dependent restriction of KSHV in primary
human umbilical vein endothelial cells (HUVECs). We initially
noted that HUVECs induced type I IFN massively and invariantly
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in response to transfection of nucleic acids or transduction with
lentiviral particles. To prevent this effect, we used co-transfection
of siRNA against IFN regulatory factor 9 (IRF9) together with
non-targeting siRNA or siRNA against MX2 and subsequently
transduced the cells with lentiviral vectors encoding either GST or
MxB (Supplementary Fig. 3b). Infection of HUVECs with KSHV
in this setting revealed a modest MxB-dependent restriction (26%
less infected cells as compared to the control) that was fully
released uponMX2 silencing (Supplementary Fig. 3c). KSHV lytic
reporter gene expression remained only marginally above back-
ground and was therefore omitted from the analysis. Thus, MxB
inhibits KSHV early in infection, most likely at the stage of virus
entry.
MxB inhibits accumulation of HSV-1 gene products. MxB
expression blocks HIV-1 replication at an early step before
integration of proviral DNA into the host genome13. We there-
fore asked whether MxB exerts a gatekeeper function by
restricting nuclear entry of herpesviral DNA. To this end, we ﬁrst
tested the expression of HSV-1 immediate-early and early genes
at 4.5 h p.i. We carried out quantitative reverse transcription PCR
(RT-qPCR) analyses with RNA isolated from A549-GST and
A549-MxB cells infected with HSV-1 strain MacIntyre, F or C12.
In the presence of MxB, mRNA accumulation of immediate-early
genes RL2 and RS1 (encoding ICP0 and ICP4, respectively) and
early gene UL29 (encoding ICP8) was reduced 2–3-fold in the
strains MacIntyre and F (Fig. 4a, b) and 5–7.5-fold in the
recombinant strain C12 (Fig. 4c). The apparent differences
between strain C12 and the two natural strains may be explained
by different kinetics in life cycle progression, enhanced sensitivity
to MxB or a combination of both.
Our results from the RT-qPCR analyses were reﬂected in
signiﬁcantly and consistently reduced de novo expression of
immediate-early proteins ICP0 and ICP4 and early protein ICP8
in A549-MxB cells infected with HSV-1 strain MacIntyre or F
(Fig. 4d, e). As a consequence, we also observed a strong
inhibition of VP5 synthesis in both strains (Fig. 4d, e).
MxB blocks HSV-1 genome uncoating and nuclear transloca-
tion. After internalisation of HSV-1 particles into the cytoplasm,
tegument proteins begin to dissociate from the capsid, allowing
the major capsid protein VP5 to become accessible to speciﬁc
antibodies55. To study the effect of MxB on the exposure of
epitopes on the viral capsid during entry, we infected A549-GST
or A549-MxB cells with HSV-1 strain F at high MOI in the
presence of the protein synthesis inhibitor cycloheximide. Using
immunoﬂuorescence assays with an antibody directed against
VP5, we monitored the appearance of exposed VP5 epitopes in
the cytoplasm during the ﬁrst 120 min of infection. The HSV-1
VP5 signal remained undetectable during the ﬁrst 60 min of
infection, and then gradually increased at later time points. The
number of VP5-speciﬁc foci in the cytoplasm likely represented
individual capsids or capsid assemblies, and was not altered in
cells expressing MxB, suggesting that MxB did not inhibit viral
tegument dissociation (Fig. 5a). We then asked whether MxB
would interfere with trafﬁcking of HSV-1 capsids to the nuclear
envelope and/or translocation of genomic DNA into the nucleus.
We used a combined immunoﬂuorescence and click chemistry
approach to simultaneously detect individual HSV-1 capsids in
the perinuclear region and uncoated, condensed HSV-1 genome
foci in the nucleus56. EdC genome-labelled HSV-1 was added to
A549-GST and A549-MxB cells in the presence of cycloheximide
to prevent early gene transcription and replication57. Cyclohex-
imide has previously been shown not to interfere with HSV-1
genome uncoating and translocation to the nucleus56. We
assessed the accumulation of capsids in the perinuclear region
with an antibody directed against puriﬁed DNA-containing HSV-
1 capsids (anti-HC). Intriguingly, in the presence of MxB, we
observed 51% less accumulation of capsids at the nucleus 30 min
p.i., and 67% less accumulation at 120 min p.i. compared to the
control (Fig. 5b). In line with this, nuclear import of uncoated
HSV-1 genomes was strongly reduced in A549-MxB cells as
compared to A549-GST cells, where it was detectable at 30 min p.
i. and peaked at 120 min p.i. (Fig. 5c). These observations were
corroborated by qPCR measurements of the viral genome in the
nuclear fraction of A549-MxB cells in presence of cycloheximide.
For the HSV-1 strains MacIntyre, F and C12, cells with a silenced
MX2 gene exhibited a 1.4–2.2-fold increase of viral genomic DNA
in the nuclear fraction compared to the control conditions
(Supplementary Fig. 4a). The efﬁciency of MX2 silencing and the
efﬁciency of subcellular fractionation were validated in parallel
samples using qPCR of the host gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in the nucleus, and immunoblots of α-
tubulin and histone H3 as cytoplasmic and nuclear markers,
respectively (Supplementary Fig. 4b). In control siRNA-treated
cells, MxB protein was mostly associated with nuclear fractions,
consistent with previously published results14.
If MxB exerted a gatekeeper function at the NPCs or in the
distant cytoplasm, thus interfering with uncoating and/or nuclear
translocation of HSV-1 genomic DNA, we would expect more
DNA-containing capsids in the cytoplasm of MxB-expressing
cells compared to control cells. To test this hypothesis, we
Fig. 2 Ectopic expression of MxB inhibits lytic replication of HSV-1 and HSV-2. a A549 human lung adenocarcinoma cells were engineered to stably
express glutathione S-transferase (GST) or human MxB. A549-GST and A549-MxB cell lines were generated from clones with high gene expression. MxB
protein expression and intracellular localisation was assessed by immunostaining. Nuclei were stained with Hoechst 33342. Scale bar, 20 µm. b A549-GST
and A549-MxB cells were transfected with non-targeting siRNA (siNT), siRNA targeting the 3′-UTR of endogenous MX2 (siMxB UTR) or two different
siRNAs targeting the coding sequence of endogenous and overexpressed MX2 (siMxB #1, siMxB #2). At 48 h post transfection, cells were lysed for
immunoblot analysis of GST and MxB protein expression and MX2 silencing efﬁciency. GAPDH served as a loading control. c–e A549-GST and A549-MxB
cells were infected with IAV strain WSN (MOI= 0.5) for 24 h (c), VSV serotype Indiana (MOI= 0.5) for 16 h (d) or HAdV-C5 strain wt300 (MOI= 5) for
48 h (e). Viral output was measured by TCID50 assay (c, d) or immunoﬂuorescence assay (e). Bars indicate mean ± s.d., n= 3–4 biological replicates.
Unpaired two-tailed Student’s t tests with log-transformed titres: NS p≥ 0.05; *p < 0.05. f–i A549-GST and A549-MxB cells were transfected with the
indicated siRNAs. At 48 h post transfection, cells were infected with HSV-1 strain MacIntyre or F (MOI= 0.05) for 24 h (f, g), recombinant strain C12
(MOI= 0.5) for 24 h (h) or HSV-2 strain G (MOI= 0.05) for 48 h (i). Viral output was measured by TCID50 assay. Data are representative of three
independent experiments. Bars indicate mean ± s.d., n= 3 biological replicates. ANOVAs modelling log-transformed titre with cell line and siRNA as
explanatory variables: HSV-1 MacIntyre: cell line, F(1,16)= 86.442, p < 0.0001; siRNA, F(3,16)= 6.863, p= 0.003489; antagonising interaction, F(3,16)=
12.34, p= 0.000196. HSV-1 F: cell line, F(1,16)= 49.065, p < 0.0001; siRNA, F(3,16)= 6.653, p= 0.00399; antagonising interaction, F(3,16)= 8.102, p=
0.00166. HSV-1 C12: cell line, F(1,16)= 333.01, p < 0.0001; siRNA, F(3,16)= 46.05, p < 0.0001; antagonising interaction, F(3,16)= 10.47, p= 0.000471.
HSV-2: cell line, F(1,16)= 54.133, p < 0.0001; siRNA, F(3,16)= 5.455, p= 0.00891; antagonising interaction, F(3,16)= 18.121, p < 0.0001. Multiple
comparisons: ****p < 0.0001
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performed transmission electron microscopy (TEM) to image the
incoming HSV-1 particles containing viral DNA (full capsids
with electron-dense material) or lacking viral DNA (empty
particles). We infected MxB-expressing and MX2-silenced cells
with HSV-1 strain MacIntyre for 3 h in the presence of
cycloheximide and processed the samples for TEM analysis
(Fig. 6). In parallel, MX2 silencing efﬁciency was determined by
immunoblot (Supplementary Fig. 7c). The number of HSV-1
capsids in the cytoplasm or in multivesicular bodies (MVBs) was
determined in ultra-thin sections across 16 control siRNA-treated
and 22 MX2-speciﬁc siRNA-treated cells (Fig. 6e). The cytoplasm
of MxB-expressing cells exhibited mostly full capsids (Fig. 6a),
while MX2-silenced cells contained primarily empty capsids
(Fig. 6b). The plasma membrane and MVBs of both MxB-
expressing and MX2-silenced cells displayed virions containing
full capsids in approximately similar amounts (Fig. 6c, d),
representing quasi-equivalent inocula. Collectively, these data
suggest that MxB interferes with HSV-1 entry at a step after
tegument dissociation but before viral genome uncoating and
translocation into the nucleus.
HSV-1 restriction by MxB requires an intact GTPase domain.
Whereas the antiviral function of MxA depends on the GTP-
binding and GTP-hydrolysing activities, the GTPase activity of
MxB is apparently not required to inhibit HIV-1
replication9,10,13,19,20. Determinants of anti-lentivirus activity
were instead found within the amino-terminal region of
MxB17,19,58,59.
To elucidate whether the amino terminus of MxB and/or its
GTPase function were necessary for HSV-1 restriction, we made
use of the herpesvirus-inducible luciferase reporter plasmid pGL-
T9G60. The construct was transiently transfected into HeLa cells
together with increasing amounts of expression plasmids
encoding GST, wild-type MxB, the short isoform of MxB (MxB
Δ1–25), an MxB mutant where a speciﬁc residue that has been
under strong positive selection in Old World monkeys and
hominoids was converted to a residue found in New World
monkeys (MxB G51Q)21, or an MxB mutant with a point
mutation in the globular (G) domain that abrogates the GTP-
hydrolysing activity (MxB T151A)47,61. We reasoned that a
transient expression system would allow us to study the
behaviour of different MxB variants in a dose-dependent manner
without possible adverse effects of clonal selection in stable
overexpressing systems. Infection of GST-expressing cells with
HSV-1 strain MacIntyre led to a 100-fold induction of the
herpesvirus-speciﬁc luciferase reporter, irrespectively of the
amount of expressed transgene (Fig. 7a). The reporter signal
augmented with time and increasing MOI and could be
antagonised by adding the HSV-speciﬁc DNA polymerase
inhibitor phosphonoacetic acid, demonstrating that the reporter
activity was entirely dependent on progressive HSV-1 infection
(Supplementary Fig. 6c–e). Furthermore, a reporter that expresses
luciferase under the control of a cellular promoter was not
affected by increasing doses of GST, wild-type MxB or mutants
thereof (Supplementary Fig. 6b). For wild-type MxB-overexpres-
sing cells or MxB G51Q-overexpressing cells infected with HSV-1
strain MacIntyre, we observed a signiﬁcant dose-dependent
inhibition of the herpesvirus reporter as compared to the GST
control. However, this effect was not seen in cells expressing
either the short isoform or the GTPase-deﬁcient form of MxB
(Fig. 7a). Similar experiments with HSV-1 strain F and HSV-2
yielded comparable results (Supplementary Fig. 6a).
We then tested whether there was a link between anti-
herpesvirus activity and subcellular localisation of MxB, as
previously suggested for MxB in HIV-1 restriction19. The
characteristic perinuclear localisation of MxB was observed in
both MxB mutants but not in the short isoform lacking the ﬁrst
25 amino acids (Fig. 7b).
Finally, to control for antiviral activities of the different MxB
variants, we transfected HeLa cells with a similar panel of
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expression vectors but infected with the VSV-pseudotyped, HIV-
1-based luciferase reporter virus NL-Luc. In accordance with
previous ﬁndings10, amino-terminal residues that are found in the
long but not in the short isoform of MxB were indispensable for
the interference with HIV-1 infection, but the GTPase function
could be abrogated without losing the anti-HIV-1 effect
(Supplementary Fig. 5a).
Discussion
Type I IFN interferes with herpesvirus replication in both epi-
thelial and neuronal cells62. Several IFN-induced effector pro-
teins, including PKR and OAS, have been implicated in restricting
herpesvirus infection so far63,64, but the extent of their respective
contributions is difﬁcult to assess due to the elaborate evasion
strategies that the herpesviruses evolved41,42.
Here we demonstrate that MxB plays a critical role in inhi-
biting several members of the Alphaherpesvirinae and Gamma-
herpesvirinae subfamilies. In agreement with our results, murine
gammaherpesvirus 68 has already been implicated as a target of
MxB in a screen for IFN-induced antiviral factors50. The con-
tribution of MxB to the type I IFN-induced restriction of HSV-1
is highly signiﬁcant. Out of the 3-log10 inhibition imposed by IFN
treatment, 0.9–1.4 log10 could be attributed to the contribution of
MX2 (Fig. 1b, c). These observations suggest that herpesviruses
are yet to evolve effective strategies to evade the activity of MxB.
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Remarkably, the contribution of MxB to the restriction of
HSV-1 is at least as pronounced as the one of PKR63, since
silencing of PKR and MX2 resulted in comparable rescue of
reporter expression of the C12 strain (compare Fig. 1d with
Supplementary Fig. 1c). Silencing of ectopically expressed MxB
with siRNA against the coding region of MX2 led to a complete
or near-complete relieve of herpesvirus restriction (Figs. 2f–i and
3a, b). These ﬁndings indicate that MxB directly interferes with
herpesvirus replication and not indirectly, for example, by
inducing antiviral effector proteins. However, we cannot exclude
other cell-intrinsic or IFN-related factors contributing to the
activity of MxB against herpesviruses, since Vero cells (monkey-
derived cells deﬁcient in the synthesis of type I IFN) exhibited a
lower degree of inhibition compared to A549 cells (compare
Supplementary Fig. 2a with Supplementary Fig. 2e), despite
similar expression levels of human MxB (Fig. 2b and Supple-
mentary Fig. 2d). Alternatively, the differences observed in the
two cell types may be explained by differences in the cell-cycle
stage at the time of infection, given the role of MxB in cell-cycle
progression and the negative effect of S-phase inhibition on the
antiviral potency against HIV-110,47.
Available evidence suggests that MxB is rather selective with
respect to its antiviral targets (see Ref. 13 and our study). Primate
lentiviruses and herpesviruses are unrelated to each other, yet
have similar nuclear entry mechanisms at least with respect to
using the NPC as a gateway into the nucleus38. They are both
targets of MxB, whereas MxB does not affect other RNA viruses
that import their genome into the nucleus via the NPC, such as
IAV (see Ref. 12 and Fig. 2c). This supports the view that MxB
does not act by controlling transport processes through the NPC
per se47. Indeed, viruses that replicate independently of nuclear
functions, such as the rhabdovirus VSV (see Ref. 50 and Fig. 2d)
and hepatitis C virus (HCV)65, may also be targeted by MxB in
the cytoplasm. We observed a minor reduction of HAdV-C5
multi-cycle infection in A549-MxB cells (Fig. 2c) and a pro-
nounced inhibition of single-round infection (Supplementary
Fig. 5c). However, this infection could not be rescued by MX2-
speciﬁc siRNAs (Supplementary Fig. 5d), suggesting MxB-
independent effects or indirect effects of MxB on HAdV-C5
infection. For instance, the continued expression of MxB may
induce IFN and/or production of other ISGs restricting HAdV-
C5. MxB-induced gene products may be long lasting and resist
MX2 silencing, yet act as auxiliary factors against HAdV-C5. Such
a scenario has been discussed for the MxB paralog MxA in HCV
restriction66. The lack of such auxiliary factors against HIV-1
may explain the observation that endogenous MxB does not
contribute to the type I IFN-mediated inhibition of HIV-1 in
certain human cell lines67. All in all, it is debatable whether MxB
directly restricts HIV-1 infection. MxB has been reported to bind
to tubular recombinant HIV-1 capsid structures in vitro15.
However, mutations in the HIV-1 capsid rendering HIV-1
resistant to MxB do not affect the interaction of the capsid with
MxB, suggesting indirect effects in restricting HIV-1[15]. It
remains to be elucidated whether MxB targets herpesvirus capsids
and/or components of the NPC such as Nup358 or Nup214,
which are implicated in nuclear import of both HIV-1 proviral
DNA and HSV-1 genomic DNA68–71.
MxB inhibits herpesviruses at an early step in the life cycle. Our
data indicate that MxB acts at a step after virus entry and tegu-
ment dissociation from the capsid (Fig. 5a) but prior to uncoating
of viral DNA from the capsid (Fig. 6) and nuclear import of viral
DNA (Fig. 5c, Supplementary Fig. 4a). As a consequence, con-
secutive steps such as accumulation of immediate-early HSV-1
transcripts and proteins are reduced (Fig. 4).
Collectively, these observations are in agreement with the
hypothesis of a cytoplasmic gatekeeper function of MxB against
herpesviruses. It is possible that the block occurs directly at the
NPC, as suggested by the subcellular localisation of MxB (Figs. 1a,
2a and 7b). We cannot rule out, however, that MxB blocks the
microtubule-directed transport of HSV-1 capsids to the nuclear
pores, or another licencing step in the cytoplasm that renders the
capsids competent for DNA uncoating, or capsid docking to the
NPC. The latter scenario may be supported by the observation
that MxB-expressing cells had low numbers of capsids near the
nucleus (Fig. 5b).
In addition to blocking herpesvirus entry, it is possible that
MxB has antiviral activity also at later time points in the viral life
cycle, for example, during exit of newly assembled capsids from
the nucleus. While HSV protein expression could be fully rescued
when MX2 was silenced in A549-MxB cells, a complete rescue of
virus titres was not always achieved (compare Fig. 2f–i with
Supplementary Figs. 2a and 7b). Thus, we cannot exclude that
MxB impacts the production of mature, infectious virions at
multiple levels.
Examination of structural and functional features of MxB
required for inhibiting herpesvirus replication revealed that
residues within the amino-terminal 25 amino acids of the long
isoform and the GTPase function of MxB were critical for MxB
activity against HSV-1 and HSV-2 (Fig. 7a and Supplementary
Fig. 6a). This is reminiscent of the MxB paralog MxA, which
depends on a functional GTPase to inhibit many RNA and DNA
viruses in the cytoplasm13. Intriguingly, the perinuclear associa-
tion of the MxB T151A mutant was stronger than wild-type MxB
(Fig. 7b), consistent with the hypothesis that the site of MxB
Fig. 5 MxB inhibits perinuclear association of HSV-1 capsids and nuclear translocation of viral genomes. a A549-GST and A549-MxB cells were infected
with HSV-1 strain F in the presence of cycloheximide. Cells were ﬁxed at the indicated time points post infection. HSV-1 capsids were stained with anti-VP5
antibody and nuclei were stained with Hoechst 33342. Samples were analysed by confocal microscopy. Data represent the number of VP5-exposed dots
per cell. Boxes depict median, 25th and 75th percentile with mean marked with a ‘+’. Whiskers denote the 10th and 90th percentile. For each comparison,
166 cells were randomly selected. Kruskal–Wallis test with cell line and time as explanatory variables: cell line, χ2= 0.0033671, df= 1, p= 0.9537; time,
χ2= 896.1, df= 3, p < 0.0001. Pairwise Wilcoxon's rank sum tests: NS p= 1.00. Data are representative of two independent experiments. Right panels
show representative images. Scale bar, 10 µm. b, c A549-GST and A549-MxB cells were mock-infected or infected with EdC-labelled HSV-1 strain F
(puriﬁed by density gradient centrifugation, approx. 40 particles per cell) in the presence of cycloheximide and ﬁxed at the indicated time points post
infection. Nuclei were stained with DAPI, capsids were stained with anti-HC antibody and free genome foci were visualised using click chemistry. Cells
were analysed by confocal microscopy with z-series image acquisition and projection along the z-axis. Individual measurements with mean ± s.d. are
shown. Data are representative of three independent experiments. For each comparison, 51 cells were randomly selected. Representative images show
maximum projections. Scale bar, 10 μm. b Percentage of capsids per cell coinciding with the nuclear mask. ANOVA modelling fraction of capsids on
nucleus with cell line and time as explanatory variables: cell line, F(1,300)= 45.3, p < 0.0001; time, F(2,300)= 101.2, p < 0.0001; antagonising interaction,
F(2,300)= 24.91, p < 0.0001. Multiple comparisons: NS p≥ 0.05, ***p < 0.001 and ****p < 0.0001. c Number of HSV genomes per cell coinciding with the
nuclear mask. Kruskal–Wallis test with cell line and time as explanatory variables: cell line, χ2= 23.054, df= 1, p < 0.0001; time, χ2= 45.162, df= 2, p <
0.0001, antagonising interaction, χ2= 81.936, df= 5, p < 0.0001. Pairwise Wilcoxon's rank sum tests: NS p≥ 0.05; ****p < 0.0001
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04379-2
10 NATURE COMMUNICATIONS |  (2018) 9:1980 | DOI: 10.1038/s41467-018-04379-2 | www.nature.com/naturecommunications
enzymatic activity is close to this location47. It is possible that
MxB associates with the nuclear envelope and thereby interferes
with herpesvirus uncoating. However, any perinuclear localisa-
tion of MxB would not be sufﬁcient, since the non-restricting
GTPase-deﬁcient mutant MxB T151A was also found in the
perinuclear region.
The amino acid residue at position 51 in simian MxB was
shown to be under strong positive selection in Old World
monkeys and hominoids, with a glycine emerging as a ﬁxed
mutation in this primate lineage21. We thus tested whether G51
of human MxB was involved in herpesvirus restriction by
mutating the glycine to glutamine as seen in New World
monkeys. However, this conversion did not alter the activity of
MxB against HSV-1 (Fig. 7a), which leaves the origin of selection
pressure at this residue unknown. We suggest that in catarrhine
species, MxB restricts pathogens beyond herpesviruses and
lentiviruses21.
Evidently, the GTP hydrolysis-mediated conformational
change of MxB47 is indispensable for its activity against herpes-
viruses, while the amino-terminal region upstream of the G
domain of MxB appears to be sufﬁcient for the inhibition of HIV-
119. This points at distinct inhibitory mechanisms of MxB against
HSV-1 and HIV-1. Nevertheless, the fact that the amino terminus
of MxB is important for restricting both HSV-1 and HIV-1, and
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Fig. 6 MxB inhibits HSV-1 genome uncoating. a–d A549-MxB cells were transfected with the indicated siRNAs. At 60 h post transfection, cells were
infected with HSV-1 strain MacIntyre (MOI= 500) in the presence of cycloheximide. Cells were ﬁxed 3 h post infection and subjected to TEM analysis.
Black arrows: full capsids; black arrowheads: empty capsids; open arrows: extracellular virions at the plasma membrane; open arrowheads: virions in
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that both viruses are blocked at an early post-entry step, at or
before uncoating of viral genomes, argue for a common direct or
indirect cytoplasmic gatekeeper function of MxB.
Methods
Cell lines. Human glioblastoma cells T98G (CRL-1690), human lung adeno-
carcinoma cells A549 (CRM-CCL-185), African Green Monkey kidney epithelial
cells Vero E6 (CRL-1586), HEK-293T (CRL-11268) and HeLa cells (CCL-2) were
purchased from ATCC. Cells were cultured in growth medium (Dulbecco’s
modiﬁed Eagle's medium (DMEM, high glucose) supplemented with 10% foetal
bovine serum (FBS), 200 µM GlutaMAX, 100 IU/ml penicillin and 100 µg/ml
streptomycin (Life Technologies)) at 37 °C and 5% CO2. Primary HUVECs (CRL-
1730, ATCC, kindly provided by Mirco Ponzoni, IRCCS Istituto G. Gaslini,
Genova, Italy) were cultured on plates pre-coated with collagen derived from rat
tail tendon (Merck) in HUVEC medium (EBM-2 endothelial growth basal medium
(CC-3156, Lonza) supplemented with EGM-2 Endothelial Growth SingleQuot Kit
Supplement and Growth Factors (CC-4176, Lonza)) at 37 °C and 5% CO2. For the
generation of stably transduced A549 and Vero cell lines, full-length Schistosoma
japonicum GST (GSTM1, accession no. FN315690.1) and full-length Homo sapiens
MX2 (accession no. nM_002463.1) complementary DNAs (cDNAs) were cloned
into the lentiviral expression vector pLVX-IRES-Puro (Clontech) using the XhoI
and XBaI restriction sites to obtain pLVX-GSTM1-IRES-Puro or the XhoI and
NotI restriction sites to obtain pLVX-MX2-IRES-Puro. Lentiviral particles were
produced in HEK-293T cells with pCMVR8.91-Gag-Pol and pVSV-G (Clontech)
together with the lentiviral expression constructs. A549 and Vero cells were
transduced with the packaged expression vectors and clones with high gene
expression were selected and maintained with 5 µg/ml puromycin (Invivogen). As a
quality control, the identity of the stable A549 and Vero clones was conﬁrmed by
sequencing.
Plasmids. For transient overexpression experiments, full-length GSTM1 and MX2
cDNAs plus the cDNA fragment encoding the short isoform of MxB (MxB Δ1–25,
base pairs 76–2148 of MX2 cDNA) were cloned into pCDNA3.1-Neo(+) expres-
sion vector (Invitrogen) using the NotI and XbaI restriction sites. The MX2(G51Q)
and MX2(T151A) mutant vectors were generated by site-directed mutagenesis
(QuikChange II XL, Agilent Technologies) according to the manufacturer’s
instructions. The herpesvirus-speciﬁc luciferase reporter plasmid pGL-T9G has
previously been described60.
Viruses. All viruses used in this study apart from KSHV were grown on A549 cells
at 37 °C and 5% CO2 and their infectious titres were determined on A549 cells
(expressed as median tissue culture infective dose, TCID50, as estimated by the
Spearman–Kaerber method) unless speciﬁed otherwise. HSV-1 strain MacIntyre
(VR-539) and strain F (VR-733) were purchased from ATCC. HSV-1 strain C12
has previously been described48 and was kindly provided by S. Efstathiou (Uni-
versity of Cambridge, Cambridge, UK). HSV-2 strain G (ATCC, VR-734) was
grown at 34.5 °C and 5% CO2. IAV strain WSN (A/WSN/1933 (H1N1)) was grown
and titrated by plaque assay on Madin–Darby canine kidney cells in the presence of
0.5 µg/ml tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma-
a
HSV-1 MacIntyre
GST
MxB
GAPDH
% MxB4300 0 14 100 16 64 205 10 48 126 11 34 93
R
el
at
iv
e 
he
rp
es
vi
ru
s 
re
po
rt
er
 a
ct
iv
ity
1.0
0.0
0.4
**** NS ********
1.2
0.8
0.6
0.2
HSV-1 MacIntyre
GST
–
GST
+
MxB
wt
+
MxB
G51Q
+
MxB
T151A
+
MxB
Δ1–25
+
37.5 ng
75 ng
150 ng
M
xB
 w
t
M
xB
 Δ
1-
25
M
xB
 G
51
Q
MxB
DNA
G
S
T
b
M
xB
 T
15
1A
MxB
1.4
15
25kDa
35
40
75
100
55
Fig. 7 HSV-1 restriction by MxB is speciﬁed by its amino terminus and requires GTPase function. a HeLa cells were transiently transfected with pGL-T9G
reporter plasmid together with increasing amounts of expression plasmids encoding the indicated proteins. At 24 h post transfection, cells were mock-
infected or infected with HSV-1 strain MacIntyre (MOI= 0.5). Virus infection efﬁciency was determined by luciferase assay at 32 h post infection and is
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Aldrich). HAdV-C5 (wt300) has previously been described29. Recombinant
Kaposi’s sarcoma-associated herpesvirus (rKSHV.21951) was obtained from
BrK.219 cells72 (generously provided by Thomas Schulz, Hannover Medical School,
Hannover, Germany) treated with Roswell Park Memorial Institute (RPMI) 1640
medium (Life Technologies) containing 0.625 μg/ml anti-human IgM (μ-chain-
speciﬁc, Southern Biotech), 0.05 μg/ml 12-O-tetradecanoylphorbol-13-acetate and
8% FBS. Cell-free supernatants were centrifuged at 30,000 × g and 4 °C for 2 h and
titres of virus concentrates were determined by ﬂow cytometric analysis of GFP-
positive HEK-293T cells 48 h p.i. on a FACSCanto II (BD Biosciences). EdC
genome-labelled HSV-1 was generated and puriﬁed as follows. A549 cells were
infected with HSV-1 strain F at a low MOI and incubated until a complete cyto-
pathic effect developed. EdC was added to the cells at 4 h p.i. to a ﬁnal con-
centration of 2.5 µM. EdC was synthesised as described73. Extracellular medium
was harvested and the cellular debris was removed by low-speed centrifugation.
The virus-containing supernatant was centrifuged at 27,500 × g and 4 °C for 90
min. The resulting pellets were resuspended by gentle shaking overnight at 4 °C in
MNT buffer (30 mM
2-(N-morpholino)ethanesulfonic acid, 100 mM NaCl, 20 mM Tris-HCl, pH= 7.4).
After waterbath soniﬁcation (three times for 30 s each at 4 °C), the suspension was
layered on top of a discontinuous Nycodenz® gradient (20% and 30% Nycodenz®,
SERVA Electrophoresis GmbH, Heidelberg) and centrifuged at 140,000 × g and
4 °C for 2 h. The virus-containing band accumulated at the interface was collected,
aliquoted, snap frozen in liquid nitrogen and stored at −80 °C.
RNA interference. Transfection of siRNA was performed using Lipofectamine
RNAiMAX reagent (Life Technologies) according to the manufacturer’s standard
reverse transfection protocol, unless stated otherwise. Brieﬂy, transfection com-
plexes were prepared using 30 nM siRNA and 1 µl transfection reagent in a 24-well
format, unless stated otherwise. Cells in suspension were added to the complexes
and incubated for 24 h at 37 °C. Transfection complexes were removed by washing
with phosphate-buffered saline (PBS) and cells were incubated for another 24 h in
growth medium. The siRNAs used in this study were purchased from Qiagen
(siNT, custom siRNA, target sequence 5′-AAG CGT TCG TCC TAT GAT CGA-
3′; siMxB UTR, Cat. No. SI00038206, target sequence 5′-CAG CAT TGT AAC
TGC TTA ATA-3′; siMxB #1, Cat. No. SI00038220, target sequence 5′-TAG GCA
TAC TTG CAA CTA ATA-3′; siRPS27A, custom siRNA, target sequence 5′-GCT
GGA AGA TGG ACG TAC T-3′) and Dharmacon (siMxB #2, Cat. No. D-011736-
01, target sequence 5′-GAG CAC GAU UGA AGA CAU A-3′).
Indirect immunoﬂuorescence assays. Cells grown on glass coverslips were ﬁxed
with 3% (w/v) paraformaldehyde (PFA) in PBS for 10 min. Subsequent permea-
bilisation and antibody staining was performed using PBS supplemented with 50
mM NH4Cl, 0.1% (w/v) saponin and 2% (w/v) bovine serum albumin (BSA, Roth
AG, Arlesheim). Primary antibodies used were goat anti-MxB (Santa Cruz Bio-
technology, sc-47197, 1:50), mouse anti-HSV-1/2 VP5 (Abcam, ab6508, 1:200),
rabbit anti-HC polyclonal antibody (PAb) (directed against puriﬁed DNA-
containing HSV-1 capsids, kindly donated by R. Eisenberg and G. Cohen, Uni-
versity of Pennsylvania, Philadelphia, USA, 1:1000) and rat anti-LANA (Advanced
Biotechnologies Inc., #13-210-100, 1:500). Secondary antibodies used were donkey
anti-goat IgG coupled to Alexa Fluor 488, goat anti-mouse IgG-AF568, goat anti-
rabbit IgG-AF568 and/or goat anti-rat IgG-AF555 (all from Life Technologies,
1:1000). DNA was counterstained using Hoechst 33342 (Life Technologies, 1:5000).
Fluorescence images were recorded on a Leica TCS SP5 confocal laser scanning
microscope (Leica Microsystems) maintained by the Center for Microscopy and
Image Analysis, University of Zurich. To visualise the localisation of MxB in T98G
cells, deconvolution was applied using Huygens version 17.04.
IFN treatment prior to viral infection. T98G cells were treated with 500 IU/ml
recombinant human IFN-α2 (Roferon-A, Roche Pharmaceuticals) 18 h prior to
virus infection. During and after virus inoculation, the IFN was omitted.
Infection of T98G cells and epithelial cell lines. Unless indicated otherwise, cells
were inoculated with the indicated MOI in infection medium (DMEM, high glu-
cose, supplemented with 0.2% (w/v) BSA, 20 mM 4-[2-hydroxyethyl]-1-piper-
azineethanesulfonic acid (HEPES), 200 µM GlutaMAX, 100 IU/ml penicillin and
100 µg/ml streptomycin (Thermo Fisher Scientiﬁc)) for 30 min at room tempera-
ture, washed with PBS, and then maintained in infection medium at 37 °C and 5%
CO2 for the indicated time periods. For IAV, 0.5 µg/ml TPCK-treated trypsin
(Sigma-Aldrich) was added to the infection medium after inoculation. For HAdV-
C5, cells were inoculated at 37 °C and 5% CO2 for 120 min in 2% FBS medium
(DMEM, high glucose, supplemented with 2% FBS, 200 µM GlutaMAX, 100 IU/ml
penicillin and 100 µg/ml streptomycin (Thermo Fisher Scientiﬁc)). Cells were
washed twice in 2% FBS medium and then incubated with 2% FBS medium at 37 °
C and 5% CO2. HAdV-C5 was quantiﬁed from intracellular and extracellular virus
obtained by scraping cells into the culture supernatant, snap freezing in liquid
nitrogen and lysing with three consecutive freeze–thaw cycles. Lysates were cen-
trifuged at 1000 × g for 5 min and titrated on fresh A549 cells. Number of infectious
particles per ml was determined by ﬁxing cells in 4% (w/v) PFA after 21 h,
quenching with 25 mM NH4Cl, permeabilising with 0.5% Triton X-100 and
immunostaining with rabbit anti-protein VI antibody74. For HSV-1 strain C12, the
infected cell cultures were maintained in 2% FBS medium and GFP ﬂuorescence
was monitored at 1–3 h intervals using the IncuCyte Zoom Live Cell Analysis
System (Essen Bioscience). For HSV-2, inoculation was performed in 2% FBS
medium for 60 min at 34.5 °C and 5% CO2. Cells were then washed with PBS and
incubated with 2% FBS medium at 34.5 °C and 5% CO2. For IAV, VSV, HSV-1 and
HSV-2 virus titre determination, supernatants from infected cell cultures were
centrifuged at 1500 × g and 4 °C for 10 min and titrated on fresh A549 cells using
TCID50 assay. For KSHV, cells were spinoculated for 1 h at 800 × g and 4 °C in
growth medium and then shifted to 37 °C and 5% CO2. At 48 h p.i., cells were ﬁxed
with 1% (w/v) PFA and GFP expression was measured on an LSR II Fortessa ﬂow
cytometer (BD Biosciences) and analysed using FlowJo version 10.2.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and immunoblot
assays. Cells were washed in ice-cold PBS and lysed with radio-
immunoprecipitation buffer (20 mM Tris-HCl, pH= 7.4, 100 mM NaCl, 1% NP-
40, 0.1% (w/v) sodium dodecyl sulphate, 1% (w/v) sodium deoxycholate, 50 mM
NaF, 50 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM ethylenediaminete-
traacetic acid, 1 mM dithiothreitol and cOmplete™ Protease Inhibitor Cocktail
(Roche Applied Science)) for 10 min on ice. Lysates were cleared using QIAsh-
redder spin columns (Qiagen), boiled in Laemmli buffer and resolved on
NuPAGE™ 4–12% polyacrylamide gels (Invitrogen). Proteins were transferred onto
a nitrocellulose membrane and stained using the following antibodies: goat anti-
MxB (Santa Cruz Biotechnology, sc-47197, 1:500), rabbit anti-MxA (Novus Bio-
logicals, H00004599-D01P, 1:1000), mouse anti-HSV-1/2 VP16 monoclonal anti-
body LP175 (kindly donated by A. Minson and H. Browne, University of
Cambridge, Cambridge, UK, 1:5000), rabbit anti-GAPDH (Santa Cruz Bio-
technology, sc-25778, 1:3000) and mouse anti-GST (Santa Cruz Biotechnology, sc-
57753, 1:1000). Densitometric analyses were performed using MultiGauge
version 3.0. Values were normalised to the loading control and are represented
relative to the appropriate control condition. Uncropped scans of all immunoblots
can be found in Supplementary Figs. 8–12.
RNA extraction and HSV-1 RT-qPCR. Total RNA from infected A549-GST and
A549-MxB cells was obtained by lysis in TRIzol® Reagent (Invitrogen) and RNA
extraction using RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. DNA was digested with DNase I (Thermo Fisher Scientiﬁc), and
cDNA synthesis was performed using random primers (Promega) and SuperScript
III First-Strand Synthesis System for RT-PCR (Invitrogen). cDNA from viral
transcripts was quantiﬁed by qPCR using GAPDH gene as endogenous control and
primers speciﬁc for the RL2, RS1 and UL29 genes using SYBR green (Life Tech-
nologies). HSV-1 cDNA sequences were ampliﬁed at the following conditions: 3
min at 95 °C, 39× (15 s at 95 °C, 60 s at 45 °C), 10 s at 95 °C, 5 s at 65 °C, 5 s at 95 °
C. The following primers were used (in 5′–3′ orientation): RL2-forward: CCT GTC
GCC TTA CGT GAA CA and RL2-reverse: ACA CGG ATT GGC TGG TGT AG;
RS1-forward: GTG AGA CCC GAA GAC GCA AT and RS1-reverse: CAT CTC
TAC CTC AGT GCC GC; UL29-forward: TGG CTT TTC GGA CTA CAC CC and
UL29-reverse: TTC GAA GGC CGT GAA CGT AA; GAPDH-forward: GAA GGT
GAA GGT CGG AGT C and GAPDH-reverse: GAA GAT GGT GAT GGG ATT
TC. Ct values were normalised to GAPDH (ΔCt) and relative virus mRNA levels
were calculated using the 2−ΔΔCt method.
Assays for HSV-1 protein expression and HSV-1 VP5 exposure. A549-GST and
A549-MxB cells were inoculated with HSV-1 strain F at the indicated MOI in 2%
FBS medium for 60 min on ice in the presence or absence of 100 µg/ml cyclo-
heximide (Sigma-Aldrich). The inoculum was removed and replaced with 2% FBS
medium with or without 100 µg/ml cycloheximide. Cells were incubated at 37 °C
for the indicated time periods, washed twice in PBS and ﬁxed with 3% (w/v) PFA in
PBS for 10 min. Fixed samples were permeabilised with 0.5% Triton X-100 in PBS
for 5 min, washed three times, and then blocked with 5% goat serum for 30 min at
room temperature. HSV-1 major capsid protein was stained using mouse anti-
HSV-1/2 VP5 antibody (Abcam, ab6508, 1:200). For staining of HSV-1 immediate-
early and early proteins, rabbit anti-ICP0 PAb (kindly provided by Ben Hale,
1:100), mouse anti-ICP4 (Abcam, ab6514, 1:2500) and mouse anti-ICP8 (Abcam,
ab20193, 1:100) antibodies were used. Secondary antibodies used were goat anti-
rabbit IgG-AF488 or goat anti-mouse IgG-AF488 (Life Technologies, 1:1000).
DNA was counterstained using Hoechst 33342 (Life Technologies, 1:5000).
Fluorescence images were recorded on a Leica TCS SP5 confocal laser scanning
microscope (Leica Microsystems) maintained by the Center for Microscopy and
Image Analysis, University of Zurich. For quantiﬁcation of VP5 exposure, a region
of interest (ROI) along the central focal plane around each cell nucleus (deﬁned by
the DNA counterstain and subsequently enlarged to cover the cytoplasm around it)
was determined and VP5-positive foci within each ROI were quantiﬁed. For
quantiﬁcation of ICP0, ICP4, ICP8 and VP5 de novo protein expression at early
time points of infection, the mean ﬂuorescence intensity in the nucleus (deﬁned by
the DNA counterstain) was determined. All data were quantiﬁed using custom-
made ImageJ version 1.48 macros.
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Analysis of HSV-1 capsid and genome localisation. A549-GST and A549-MxB
cells were inoculated with EdC genome-labelled HSV-1 strain F for 1 h on ice with
constant rocking in RPMI 1640 medium (Life Technologies) containing 0.2% (w/v)
BSA and 20 mM HEPES to allow virus binding. After this period, cells were washed
twice with fresh medium and either ﬁxed immediately in 4% (w/v) PFA in PBS or
ﬁxed at intervals after incubation at 37 °C and 5% CO2 in the presence of 100 µg/ml
cycloheximide (Sigma-Aldrich) to prevent synthesis of viral proteins. For detection
of incoming capsids, cells were stained with rabbit anti-HC PAb. After immu-
nostaining, viral genomes were visualised using Copper(I)-catalysed azide alkyne
cycloaddition (click) as previously described28. Brieﬂy, samples were stained for 2 h
at room temperature with freshly prepared click chemistry staining mix containing
10 µM AF488-azide (Life Technologies), 1 mM CuSO4 (Sigma-Aldrich), 10 mM
sodium ascorbate (Sigma-Aldrich), 10 mM amino-guanidine (Sigma-Aldrich) and
1 mM Tris(hydroxypropyltriazolyl)methylamine (Sigma-Aldrich). Samples were
stained with 4′,6-diamidino-2-phenylindole (DAPI, Life Technologies) for cell
nuclei and succinimidyl ester-AF647 (Life Technologies) for cell outlines, and
embedded in DAKO medium (Dako Schweiz AG, Baar). Fluorescence images were
recorded on a Leica TCS SP8 confocal laser scanning microscope (Leica Micro-
systems) maintained by the Center for Microscopy and Image Analysis, University
of Zurich. Images were analysed using a custom-made CellProﬁler version 2.1.1
pipeline and KNIME version 2.12.2.
Transmission electron microscopy. A549-MxB cells pretreated with siRNA were
spinoculated with HSV-1 strain MacIntyre (MOI= 500, virus stock produced in
2% FBS medium and supplemented with 20 mM HEPES prior to inoculation) at
800 × g and 4 °C for 60 min in the presence of 100 µg/ml cycloheximide (Sigma-
Aldrich). The inoculum was removed and cells were incubated in infection med-
ium in the presence of 100 µg/ml cycloheximide for 3 h. Samples were processed
for TEM and analysed by TEM on a Zeiss EM 902A with modiﬁcations of pre-
viously published protocols76. Prior to ﬁxation, cells were washed twice with warm
PBS containing 1 mM CaCl2 and 0.5 mM mgCl2 (PBS+ Ca/Mg). Cells were ﬁxed
in 2% glutaraldehyde in PBS+ Ca/Mg for 30 min at room temperature. Prepara-
tion of samples for TEM was performed as follows. Post-ﬁxation: short wash in
PBS, 3× wash in H2O for 5 min, incubation with 1% osmium tetroxide+ 1.5%
potassium ferricyanide in H2O at 4 °C for 1 h, 3× wash in PBS for 3 min, 2× wash
in H2O for 5 min and incubation with 2% uranyl acetate in H2O overnight at 4 °C.
Sample dehydration: 30% acetone for 5 min, 50% acetone for 5 min, 70% acetone
for 30 min, 90% acetone for 10 min, 100% acetone for 5 min and 100% acetone for
10 min. Sample embedding: 48% epoxy resin, 16% dodecenyl succinic anhydride,
34% methyl nadic anhydride and 2% benzyldimethylamine. Resin was allowed to
polymerise at 60 °C for 2 days. Sample mounting, staining and imaging: ultra-thin
sections (85 nm) obtained with a Leica Ultracut UCT ultramicrotome (Leica
Microsystems) were mounted on copper grids with parlodion-carbon support ﬁlm,
placed sideways on a droplet of 2% uranyl acetate in H2O for 30 min, immersed
repeatedly in H2O, air dried overnight, placed sideways on a droplet of Sato’s lead
staining solution for 20 min, immersed repeatedly in H2O, air dried for 30 min and
imaged at 80 kV and ×50,000 magniﬁcation.
Herpesvirus luciferase reporter assay. Transient transfections were performed
using jetPRIME® reagent (Polyplus Transfection) according to the manufacturer’s
instructions. Transfection complexes were prepared at a DNA:transfection reagent
ratio of 1:2 with a total amount of 500 ng DNA per well (24-well plate assay
format). Speciﬁcally, 200 ng pGL-T9G and increasing amounts of expression
plasmids were used (37.5, 75 and 150 ng). The total amount of DNA per well was
adjusted using the empty expression plasmid. After the infection period, luciferase
activity was determined using the BrightGlo™ Luciferase Assay System (Promega)
on an Envision 2104 plate reader (Perkin Elmer).
Transient overexpression for analysis of MxB localisation. Transient trans-
fections for immunoﬂuorescence analysis of MxB variants were performed using
ViaFect™ reagent (Promega) according to the manufacturer’s instructions. Trans-
fection complexes were prepared at a DNA:transfection reagent ratio of 1:3 with a
total amount of 500 ng expression plasmid per well (24-well plate assay format).
Statistical analyses. Statistical analyses were performed using R version 3.4.177.
Individual statistical tests are speciﬁed within the ﬁgure legends. Count data with
more than two groups were analysed by Kruskal–Wallis test and pairwise Wil-
coxon's rank sum tests. All other grouped data were analysed by analysis of var-
iance (ANOVA) under consideration of the assumptions of normality and
homogeneity of variance78. Multiple comparison tests with user-deﬁned contrasts
were performed with the glht function in the multcomp package. For non-
orthogonal multiple comparisons, α-levels were corrected according to Holm’s
method79.
Code availability. Computer code used for immunoﬂuorescence image quantiﬁ-
cation is available on https://github.com/greberlab/2018_NatComm_MxB.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles, or are
available on request.
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